Annual results and Q4 2022
Wednesday, February 01, 2023

Media release:

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.5 MB)

Watch the webcast

Download the presentation (PDF 5.1 MB)

Download the podcast (MP3 45 MB)
 

Key figures1 Q4 2022
(USD m)		 Q4 2021
(USD m)		 % change
(USD/cc)
Net sales 12,690 13,229 -4 (cc: 3)
Operating income 1,949 2,562 -24 (cc: -14)
Net income 1,466 16,306 -91 (cc: -90)
EPS (USD) 0.69 7.29 -91 (cc: -89)
Free cash flow 3,552 3,027 17

Core		      
Operating income 4,030 3,819 6 (cc: 15)
Net income 3,251 3,135 4 (cc: 14)
EPS (USD) 1.52 1.40 9 (cc: 19)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Q3 2022 results - Tuesday, October 25, 2022

Media release:

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Interim financial report (PDF 0.5 MB)

Watch the webcast

Download the presentation (PDF 3.7 MB)

Download the podcast (MP3 40 MB)

Read the presentation transcript

Novartis ESG Update - October 31, 2022 (PDF 0.5 MB)
 

Key figures1 Q3 2022
(USD m)		 Q3 2021
(USD m)		 % change
(USD/cc)
Net sales 12,543 13,030 -4 (cc: 4)
Operating income 2,168 3,233 -33 (cc: -23)
Net income 1,575 2,758 -43 (cc: -33)
EPS (USD) 0.73 1.23 -41 (cc: -31)
Free cash flow 4,169 4,423 -6

Core		      
Operating income 4,282 4,467 -4 (cc: 5)
Net income 3,419 3,830 -11 (cc: -2)
EPS (USD) 1.58 1.71 -8 (cc: 1)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 49 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

Q2 2022 results - Tuesday, July 19, 2022

Media release:

English (PDF 0.2 MB) | Deutsch (PDF 0.2 MB) | Français (PDF 0.2 MB)

Interim financial report (PDF 0.5 MB)

Watch the webcast

Download the interactive presentation (PDF 2.9 MB)

Download the podcast (MP3 42 MB)

Read the presentation transcript

Novartis ESG Update - July 20, 2022 (PDF 0.4 MB)

Key figures1

  Q2 2022
(USD m)		 Q2 2021
(USD m)		 % change
(USD/cc)
Net sales 12,781 12,956 -1 (cc: 5)
Operating income 2,228 3,479 -36 (cc: -30)
Net income 1,695 2,895 -41 (cc: -34)
EPS (USD) 0.77 1.29 -40 (cc: -33)
Free cash flow 3,304 4,235 -22

Core		      
Operating income 4,270 4,345 -2 (cc: 5)
Net income 3,431 3,716 -8 (cc: -1)
EPS (USD) 1.56 1.66 -6 (cc: 1)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Q1 2022 results - Tuesday, April 26, 2022

Media release:

English (PDF 0.2 MB) | Deutsch (PDF 0.2 MB) | Français (PDF 0.2 MB)

Interim financial report (PDF 0.4 MB)

Watch the webcast

Download the interactive presentation (PDF 4.1 MB)

Download the podcast (MP3 40 MB)

Read the presentation transcript

Novartis ESG Update - April 27, 2022 (PDF 0.7 MB)


Key figures1

  Excluding Roche investment impacts2 Reported
  Q1 2022
(USD m)		 Q1 2021
(USD m)		 % change
(USD/cc)		 Q1 2021
(USD m)		 % change
(USD/cc)
Net sales 12,531 12,411 1 (cc: 5) 12,411 1 (cc: 5)
Operating income 2,852 2,415 18 (cc: 26) 2,415 18 (cc: 26)
Net income 2,219 1,803 23 (cc: 32) 2,059 8 (cc: 15)
EPS (USD) 1.00 0.80 25 (cc: 34) 0.91 10 (cc: 17)
Free cash flow 920 1,075 -14 1,597 -42

Core		          
Operating income 4,083 3,957 3 (cc: 9) 3,957 3 (cc: 9)
Net income 3,251 3,100 5 (cc: 11) 3,413 -5 (cc: 0)
EPS (USD) 1.46 1.38 6 (cc: 12) 1.52 -4 (cc: 2)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 35 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. A reconciliation of 2021 IFRS results and non-IFRS measures core results and free cash flow to exclude the impacts of the 2021 divestment of our Roche investment can be found on page 40 of the Condensed Interim Financial Report. The free cash flow impact represents the dividend received in Q1 2021 from Roche in relation to the distribution of its 2020 net income.

2021 Quarterly Results

Q4 2021 Media Release (PDF 0.3 MB)

Q4 2021 Financial Report (PDF 0.5 MB)

Reconciliation of 2021 results excluding Roche investment impacts (PDF 0.5 MB)

Q3 2021 Media Release (PDF 0.3 MB)

Q3 2021 Financial Report (PDF 0.5 MB)

Q2 2021 Media Release (PDF 0.4 MB)

Q2 2021 Financial Report (PDF 0.5 MB)

Q1 2021 Media Release (PDF 0.2 MB)

Q1 2021 Financial Report (PDF 0.4 MB)

2020 Quarterly Results

Q4 2020 Media Release (PDF 0.2 MB)

Q4 2020 Financial Report (PDF 0.9 MB)

Q3 2020 Media Release (PDF 0.2 MB)

Q3 2020 Financial Report (PDF 0.8 MB)

Q2 2020 Media Release (PDF 0.1 MB)

Q2 2020 Financial Report (PDF 0.8 MB)

Q1 2020 Media Release (PDF 0.2 MB)

Q1 2020 Financial Report (PDF 0.6 MB)

2019 Quarterly Results

Q4 2019 Media Release (PDF 0.1 MB)

Q4 2019 Financial Report (PDF 0.7 MB)

Q3 2019 Media Release (PDF 0.1 MB)

Q3 2019 Financial Report (PDF 0.8 MB)

Q2 2019 Media Release (PDF 0.2 MB)

Q2 2019 Financial Report (PDF 0.6 MB)

Q1 2019 Media Release (PDF 0.5 MB)

Q1 2019 Financial Report (PDF 0.5 MB)

2018 Quarterly Results

Q4 2018 Media Release (PDF 0.1 MB)

Q4 2018 Financial Report (PDF 0.6 MB)

Q3 2018 Media Release (PDF 0.1 MB)

Q3 2018 Financial Report (PDF 0.7 MB)

Q2 2018 Media Release (PDF 0.1 MB)

Q2 2018 Financial Report (PDF 0.5 MB)

Q1 2018 Media Release (PDF 0.1 MB)

Q1 2018 Financial Report (PDF 0.5 MB)

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.